Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia

StatusUnknown
PhasePhase 2
Started

Record status This record was last updated September 25, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v3
  3. Primary completion date: Jan 31, 2027 to Dec 31, 2024v2 Show 5 more changesShow less
    • Study completion date: Jun 30, 2027 to Dec 31, 2025
    • Interventions: Cyclophosphamide added to standard immunosuppressive therapy with eltrombopag (Drug) to Cyclophosphamide added to standard immunosuppressive therapy with herombopag (Drug)
    • Eligibility criteria revised
    • Secondary endpoints: details revised at 1 of 4 entries
    • Study title revised
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, single-center, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of Anti-lymphocyte globulin plus herombopag in combination with moderate-dose cyclophosphamide for severe aplastic anemia.
Trial Details
NCT Number NCT05975996
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions
(from sponsor)		 Severe Aplastic Anemia
Related terms Anemia, Aplastic
Enrollment 43 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov